IQVIA

IQVIA offers several platforms that can be used across healthcare verticals, including healthcare operation management and life science technology. Its life sciences technology platform solutions assist companies with regard to clinical trial planning, compliance, obtaining real world evidence, and generating insights.

The company also offers solutions for medical adherence, healthcare operation optimization, brand strategy, and patient engagement. IQVIA is the subsidiary of public-listed healthcare technology company, IQVIA Holdings Inc. (NYSE:IQV).

In April 2021, IQVIA acquired 40% interest in Q2 Solutions for a consideration of USD 760 million. This transaction resulted in IQVIA gaining 100% ownership of Q2 Solutions.

Key customers and partnerships

In October 2023, IQVIA expanded its partnership with argenx, a biotechnology company, to advance autoimmune care. Through the partnership, the companies will collaborate to accelerate the expansion of clinical development and commercialization of new indications in autoimmune diseases. The partnership will involve IQVIA developing technology solutions tailored to argenx’s needs.

In April 2024, IQVIA expanded its partnership with Salesforce, a global cloud computing company, to accelerate the development of Salesforce’s Life Sciences Cloud, a customer engagement platform for the global life sciences sector. Using IQVIA's Orchestrated Customer Engagement (OCE) platform, which comprises data and analytics features, and Salesforce's Customer Relationship Management (CRM) solutions, the companies aimed to create a solution to provide an end-to-end engagement platform for life science companies. IQVIA agreed to license its engagement platform and associated software to Salesforce for the platform’s development. The companies projected that Salesforce Life Sciences Cloud would be ready for launch in 2025.

Funding and financials

In November 2023, IQVIA raised USD 500 million through an offering of senior secured notes due in 2029. The proceeds were earmarked to settle outstanding term loans, restructuring its previous credit facilities in a new term B loan valued at USD 1.25 billion. The funds were additionally set aside to pay fees and expenses associated with facilitating the current loan agreements and the term B loan. These activities, however, were subject to the fulfillment of customary conditions and any other possible changes in market conditions. After the note offering and restructuring of its loan facilities, the company planned to enter one or more currency swap agreements to mitigate exposure to its USD-based loan facilities.